Chemoimmunotherapy enables adaptive strategies in locally advanced MSS colorectal cancer.

Early exposure to checkpoint blockade restores immune-sensitivity in localized, immune-excluded cancers. In this issue of Med, Zhang et al. reported promising pathological activity of 3-month preoperative cadonilimab (bispecific anti-PD-1/CTLA-4 antibody) with modified FOLFOXIRI triplet intensive chemotherapy in patients with locally advanced MSS colorectal adenocarcinoma, hinting to new adaptive strategies of radiotherapy-sparing and organ preservation.1.